Shire To Launch Potential Dry Eye Blockbuster After FDA Backs Xiidra

Securing FDA approval for its novel dry eye treatment Xiidra (lifitegrast) gives Shire PLC a potential blockbuster and key future growth driver whose indication and label are more comprehensive than that of its closest approved rival.

Vision

FDA approval of Shire PLC's Xiidra (lifitegrast ophthalmic solution) for treating dry eye came 10 days earlier than expected and paves the way for the product's launch in the third quarter of 2016 as the only prescription eye drop approved in the US specifically to treat both the signs and symptoms of the condition.

Xiidra’s indication for both signs and symptoms of dry eye is more comprehensive than that of the key approved competitor,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip